** Shares of Replimune REPL.O zooms 73.5% to $8.12 premarket

** The biotech firm said it would resubmit application for its experimental treatment for advanced skin cancer, after reaching an agreement with the U.S. FDA

** The treatment, RP1, also known as vusolimogene oderparepvec, is being tested with Bristol Myers Squibb's BMY.N Opdivo for patients whose advanced melanoma has worsened after prior treatment

** FDA had twice rejected the drug, citing issues in clinical trials and inadequate evidence of effectiveness

** REPL says it would resubmit the application in the coming days and FDA would treat the resubmission as an urgent matter

** As of last close, REPL down 51.9% YTD